Last reviewed · How we verify
Clarinex (desloratadine)
Active metabolite of loratadine with higher potency at H1 receptors and additional anti-inflammatory properties.
Desloratadine (Clarinex/Aerius) is the active metabolite of loratadine, approved in 2001. More potent with additional anti-inflammatory properties. Available generically in many markets.
At a glance
| Generic name | desloratadine |
|---|---|
| Also known as | Clarinex, Aerius |
| Sponsor | Generic (originally Schering-Plough/MSD) |
| Drug class | Histamine-1 Receptor Antagonist [EPC] |
| Target | 5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2001-12-21 (United States) |
Mechanism of action
Desloratadine is the active metabolite of loratadine, approximately 10-20x more potent at the H1 receptor. It also has anti-inflammatory properties beyond simple H1 blockade, inhibiting cytokine and chemokine release from mast cells and basophils.
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Allergic urticaria
- Chronic idiopathic urticaria
- Common cold
- Nasal congestion
- Nasal discharge
- Seasonal allergic rhinitis
- Sneezing
- Vasomotor rhinitis
Common side effects
- Upper respiratory tract infections
- Diarrhea
- Fever
- Coughing
- Irritability
- Somnolence
- Bronchitis
- Vomiting
- Urinary tract infection
- Otitis media
- Anorexia
- Pharyngitis
Key clinical trials
- A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Scleros (Phase 3)
- Pilot Efficacy and Safety Field Trial of Desloratadine Administered Concomitantly With Oxybutynin, in Subjects With Seasonal Allergic Rhinitis and Post-Nasal Drip (Phase 2)
- A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR) (Phase 4)
- Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis (Phase 4)
- Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Syrup Among Filipino Pediatric Patients (N/A)
- Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Desloratadine 5 mg for the Treatment of Seasonal Allergic Rhinitis (Phase 3)
- Influence of H1-antihistamines on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin (NA)
- Peanut Allergy Oral Immunotherapy Desensitization (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |